TapImmune announced that the Food & Drug Administration (FDA) has granted Fast Track designation for its cancer vaccine TPIV 200 in the treatment of ovarian cancer.

TPIV 200 cancer vaccine is under investigation as a maintenance therapy with GM-CSF adjuvant in patients with platinum-sensitive advanced ovarian cancer, who achieved stable disease or partial response following completion of standard of care chemotherapy.

RELATED: FDA Grants Ovarian Cancer Vaccine Orphan Drug Designation

The FDA recently granted TPIV 200 Orphan Drug designation for the same indication in December 2015.

TPIV 200 is a multiple-epitope folate receptor alpha peptide vaccine.

For more information visit TapImmune.com.